ClinicalTrials.govpublic full text
Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV
hiv infections, hiv infection, highly active antiretroviral therapy, treatment naive, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 905469
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.